Analysts Issue Forecasts for CRDL Q3 Earnings

Key Points

• Brookline Capital Management predicts Cardiol Therapeutics will report Q3 2025 earnings of ($0.08) per share, with a full-year consensus estimate of ($0.33) per share.
• HC Wainwright initiated coverage with a buy rating and a price target of $9.00, contributing to a current consensus rating of Strong Buy for the stock.
• Shares of Cardiol Therapeutics opened at $1.12 and have seen a 12-month price range between $0.77 and $2.44.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Investment analysts at Brookline Capital Management issued their Q3 2025 earnings estimates for Cardiol Therapeutics in a report issued on Wednesday, September 17th. Brookline Capital Management analyst T. Bussian forecasts that the company will post earnings of ($0.08) per share for the quarter. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. Brookline Capital Management also issued estimates for Cardiol Therapeutics' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.31) EPS.

Separately, HC Wainwright started coverage on shares of Cardiol Therapeutics in a research note on Monday, June 2nd. They set a "buy" rating and a $9.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and a consensus target price of $8.00.

Cardiol Therapeutics Price Performance

NASDAQ CRDL remained flat at $1.12 on Monday. 568,562 shares of the company's stock traded hands, compared to its average volume of 686,674. Cardiol Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.44. The company has a quick ratio of 2.46, a current ratio of 2.46 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $1.19 and a two-hundred day moving average price of $1.18.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04.

Hedge Funds Weigh In On Cardiol Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in shares of Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock worth $36,000 after purchasing an additional 15,255 shares during the period. Thompson Davis & CO. Inc. purchased a new position in Cardiol Therapeutics in the 2nd quarter valued at $39,000. Cetera Investment Advisers purchased a new position in Cardiol Therapeutics in the 4th quarter valued at $56,000. Lion Street Advisors LLC lifted its holdings in Cardiol Therapeutics by 8.5% in the 1st quarter. Lion Street Advisors LLC now owns 333,725 shares of the company's stock valued at $318,000 after purchasing an additional 26,059 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new position in shares of Cardiol Therapeutics during the 4th quarter worth $624,000. Institutional investors and hedge funds own 12.49% of the company's stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.